- ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.
So says a proxy filing made after trading on Tuesday, as a couple of suitors included contingent value rights in their bids for the marketer of prostate cancer drug, Xtandi.
There are too many companies in just about every sector of this market, Cramer says.